Decision 13-D-21 of

Decision 13-D-21 of 18 December 2013 regarding practices implemented on the French market for high-dosage Buprenorphine sold in private practices

Presentation of the decision

Information about the decision

Origin of the case Arrow Génériques
Company(ies) involved
  • Schering-Plough, Financière MSD, Merck & Co, Reckitt Benckiser Healthcare (UK) Ltd, Reckitt Benckiser plc